Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2018 07:40 ET | Source: Esperion Therapeutics, Inc.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results

ANN ARBOR, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
May 02, 2018 07:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid

— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration Study —— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin...
April 13, 2018 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., April 13, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
March 27, 2018 07:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia

— Study Met Primary Endpoint with 30% Additional LDL-C Lowering — — hsCRP Reduction of 34% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Tuesday, March...
March 07, 2018 16:01 ET | Source: Esperion Therapeutics, Inc.

Esperion to Participate in Fireside Chat at March 2018 Investor Conferences

ANN ARBOR, Mich., March 07, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
March 07, 2018 07:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid

— Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin — — hsCRP Reduction of 33% — — Observed to be Safe and...
February 23, 2018 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
February 20, 2018 07:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results

ANN ARBOR, Mich., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
January 03, 2018 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference

Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
December 14, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors

ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...